Welcome to our dedicated page for Genmab news (Ticker: GMAB), a resource for investors and traders seeking the latest updates and insights on Genmab stock.
Genmab A/S (GMAB) is a global biotechnology leader focused on creating differentiated antibody therapies for cancer and autoimmune diseases. This page serves as the definitive source for Genmab news, providing investors and industry professionals with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Access consolidated information on FDA approvals, collaboration announcements, and clinical trial results across Genmab's pipeline. The company's proprietary platforms like DuoBody and HexaBody underpin its innovative treatments, with key alliances including Johnson & Johnson and AbbVie driving therapeutic advancements.
Bookmark this page for real-time updates on Genmab's progress in antibody engineering and commercialization efforts. Monitor critical updates through verified press releases while gaining insights into how the company addresses complex medical challenges through targeted biologics.
Genmab announced that it will present new and updated results from clinical trials evaluating epcoritamab at the 2024 EHA Congress. Sixteen abstracts will be presented, showcasing the depth of their epcoritamab development program. The data includes safety and efficacy results across various B-cell malignancies, such as relapsed/refractory follicular lymphoma, diffuse large B-cell lymphoma, and Richter’s transformation.
Three oral presentations will highlight key findings: single-agent epcoritamab results in Richter’s Transformation, epcoritamab combined with Pola-R-CHP for first-line treatment in diffuse large B-cell lymphoma, and epcoritamab's impact on relapsed/refractory follicular lymphoma. The presentations will occur in Madrid and virtually from June 13-16, 2024.
Genmab, in collaboration with AbbVie, continues to advance epcoritamab's development as both a monotherapy and combination therapy. The abstracts are available via the EHA Open Access Library.
The FDA has granted full approval for TIVDAK® for the treatment of recurrent or metastatic cervical cancer. TIVDAK is the first antibody-drug conjugate with positive overall survival data for patients with previously treated disease. The approval is based on results from a Phase 3 study showing an overall survival benefit compared to chemotherapy. The safety profile of TIVDAK was consistent with known information, with no new safety issues identified. Common adverse reactions included decreased hemoglobin, peripheral neuropathy, and conjunctival adverse reactions. The approval of TIVDAK brings new treatment options for patients with advanced cervical cancer and addresses the high unmet need in this patient population.
Genmab A/S and Pfizer Inc. announced that the U.S. FDA has approved TIVDAK® for recurrent or metastatic cervical cancer treatment, converting its accelerated approval to a full approval. This is the first ADC with positive overall survival data in this patient population. The approval is based on Phase 3 data showing a 30% risk reduction in death compared to chemotherapy.
FAQ
What is the current stock price of Genmab (GMAB)?
What is the market cap of Genmab (GMAB)?
